NDC 70121-1570

RELEUKO

Filgrastim

RELEUKO is a Intravenous; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Amneal Pharmaceuticals Llc. The primary component is Filgrastim.

Product ID70121-1570_0b7683ae-91e8-44b0-84a6-e185b84b5664
NDC70121-1570
Product TypeHuman Prescription Drug
Proprietary NameRELEUKO
Generic NameFilgrastim
Dosage FormInjection, Solution
Route of AdministrationINTRAVENOUS; SUBCUTANEOUS
Marketing Start Date2022-02-25
Marketing CategoryBLA /
Application NumberBLA761082
Labeler NameAmneal Pharmaceuticals LLC
Substance NameFILGRASTIM
Active Ingredient Strength480 ug/.8mL
Pharm ClassesGranulocyte Colony-Stimulating Factor [CS], Granulocyte-Macrophage Colony-Stimulating Factor [CS], Increased Myeloid Cell Production [PE], Leukocyte Growth Factor [EPC]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 70121-1570-1

1 SYRINGE in 1 BOX (70121-1570-1) > .8 mL in 1 SYRINGE
Marketing Start Date2022-02-25
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "RELEUKO" or generic name "Filgrastim"

NDCBrand NameGeneric Name
70121-1568RELEUKOFilgrastim
70121-1569RELEUKOFilgrastim
70121-1570RELEUKOFilgrastim
70121-1571RELEUKOFilgrastim
55513-209NEUPOGENFilgrastim
55513-530NEUPOGENFilgrastim
55513-546NEUPOGENFilgrastim
55513-924NEUPOGENFilgrastim

Trademark Results [RELEUKO]

Mark Image

Registration | Serial
Company
Trademark
Application Date
RELEUKO
RELEUKO
90567963 not registered Live/Pending
KASHIV BIOSCIENCES, LLC
2021-03-09
RELEUKO
RELEUKO
87594432 not registered Live/Pending
Adello Biologics, LLC
2017-09-01

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.